国产三级在线,99免费精品视频,日韩精品人妻中文字幕有码无码,午夜福利视频无码一区二区三区

  設(shè)為主頁 加入收藏 English
 
 
 
 新聞動(dòng)態(tài)
 行業(yè)動(dòng)態(tài)
 展會(huì)信息
 誠(chéng)聘英才
 
 

測(cè)量應(yīng)用案例-20211106

發(fā)布時(shí)間:2021-11-17  點(diǎn)擊次數(shù):184  新聞來源:
 

文獻(xiàn)名:Fullerenols boosting the therapeutic effect of anti-CD47 antibody to trigger robust anti-tumor immunity by inducing calreticulin exposure

 

 

 

作者 Kui Chenab, Yujiao Wanga, Haojun Lianga, Huan Huanga, Yuelan Lianga, Jiaxin Zhanga, Ya-nan Changa, Juan Lia, Min Fangc, Gengmei Xinga

aCAS Key Laboratory for Biomedical E?ects of Nanomaterial & Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China

bUniversity of Chinese Academy of Sciences, Beijing 100049, China

cCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China

 

 

摘要:Phagocyte-mediated programmed cell removal (PrCR) plays an important role in the immunosurveillance and elimination of cancer cells. The induction of PrCR is elevated by exposed calreticulin (CRT) on cell surface as a “eat me” signal, and countered by "don't eat me" signal, CD47. Thus, well-tolerated CRT exposure inducers are benefit for the outcome of anti-CD47 therapy. Herein, fullerenol nanoparticle (fNP) with special surface property is found to trigger CRT exposure in 7 out of 12 human cancer cell lines by inducing basal ER stress without the occurrence of immunogenic cell death. Increased CRT exposure by fNP elicits efficient PrCR, which is further enhanced by the combination of fNP and anti-CD47 mAb in vivo. Moreover, the combined therapy shows significantly increased anti-tumor efficiency compared with anti-CD47 mAb alone in both U87MG subcutaneous glioblastoma model and 143B orthotopic osteosarcoma model. Even in combination with half dose of anti-CD47 mAbs shows a similar anti-tumor efficiency with full-dose anti-CD47 mAbs alone, suggesting the role of fNP in reducing the amount of anti-CD47 mAbs. Moreover, the combination treatment promotes M2-to-M1 repolarization of macrophage within the tumor microenvironment. These findings validate our strategy as an effective platform for combining fNP with anti-CD47 therapy.

 

關(guān)鍵詞:Fullerenols; CRT exposure; Macrophage; PrCR; Anti-CD47 therapy

 
 
上海市普陀區(qū)嵐皋路567號(hào)1108-26室 電話:021-62665073 400-718-7758 傳真:021-62761957
美國(guó)布魯克海文儀器公司上海代表處 版權(quán)所有  管理登陸 ICP備案號(hào):滬ICP備19006074號(hào)-2 技術(shù)支持:化工儀器網(wǎng)